Int. J. Mol. Sci. 2013, 14(6), 12170-12185; doi:10.3390/ijms140612170
Article

Serum Metallothioneins in Childhood Tumours — A Potential Prognostic Marker

1 Department of Paediatric Haematology and Oncology, 2nd Medical Faculty and University Hospital Motol, V Uvalu 84, Prague CZ 150 06, Czech Republic 2 Department of Chemistry and Biochemistry, Faculty of Agronomy, Mendel University in Brno, Zemedelska 1, Brno CZ 613 00, Czech Republic 3 Central European Institute of Technology, Brno University of Technology, Technicka 3058/10, Brno CZ 616 00, Czech Republic 4 Department of Medical Chemistry and Clinical Biochemistry, 2nd Medical Faculty and University Hospital Motol, V Uvalu 84, Prague CZ 150 06, Czech Republic
* Author to whom correspondence should be addressed.
Received: 10 April 2013; in revised form: 22 May 2013 / Accepted: 30 May 2013 / Published: 6 June 2013
(This article belongs to the Special Issue Advances in Cancer Diagnosis)
PDF Full-text Download PDF Full-Text [328 KB, uploaded 6 June 2013 14:56 CEST]
Abstract: Metallothioneins (MT) are low molecular weight, cysteine-rich proteins maintaining metal ions homeostasis. They play a role in carcinogenesis and may also cause chemoresistance. The aim of the study was to explore the importance of MT serum levels in children suffering from malignant tumours. This prospective study involves examination of 865 samples from 172 patients with malignant tumours treated from 2008 to 2011 at University Hospital Motol. MT serum levels were determined using differential pulse voltammetry–Brdicka reaction. Mean MT level was 2.7 ± 0.5 μM. There was no statistically significant difference between MT levels in different tumours. We also did not find any correlation between MT levels and response to therapy or clinical stages. However, we found a positive correlation between MT levels and age (p = 0.009) and a negative correlation with absolute lymphocyte number (p = 0.001). The fact that patients who had early disease recurrence had lower MT levels during the treatment (complete remission 2.67 vs. recurring 2.34, p = 0.001) seems to be important for clinical practice. Accordingly we believe that there is benefit in further studies of serum MT levels in tumours.
Keywords: serum metallothioneins; children; solid tumours; treatment; differential pulse voltammetry Brdicka reaction

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Kruseova, J.; Hynek, D.; Adam, V.; Kizek, R.; Prusa, R.; Hrabeta, J.; Eckschlager, T. Serum Metallothioneins in Childhood Tumours — A Potential Prognostic Marker. Int. J. Mol. Sci. 2013, 14, 12170-12185.

AMA Style

Kruseova J, Hynek D, Adam V, Kizek R, Prusa R, Hrabeta J, Eckschlager T. Serum Metallothioneins in Childhood Tumours — A Potential Prognostic Marker. International Journal of Molecular Sciences. 2013; 14(6):12170-12185.

Chicago/Turabian Style

Kruseova, Jarmila; Hynek, David; Adam, Vojtech; Kizek, Rene; Prusa, Richard; Hrabeta, Jan; Eckschlager, Tomas. 2013. "Serum Metallothioneins in Childhood Tumours — A Potential Prognostic Marker." Int. J. Mol. Sci. 14, no. 6: 12170-12185.

Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert